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Multiform Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite improvement of
treatments (usually surgical resection followed by radio- and/or chemotherapy), glioblastoma patients have a poor
prognosis, mainly due to recurrences of the tumor. It has been recently shown in an orthotopic xenograft model that
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GBM cells can escape the tumor mass and specifically invade the subventricular zones (SVZ) of the adult brain. This
migration is mediated by a CXCL12 gradient that attracts GBM cells, which have been shown to express CXCR4 (one of
the two CXCL12 receptors). In addition, these CXCR4+ cells share characteristics with stem cells and are thus
considered as GBM-initiating cells responsible for the recurrences. They appear therefore as a target of choice for
therapeutic approaches. Oncolytic Herpes simplex virus (oHSV) has been shown to have potent oncolytic effects
against tumor cells of different origin, including GBM. We have engineered a herpesvirus, which specifically targets
CXCR4+ cells and is armed with genes inducing the extrinsic or/and intrinsic apoptosis signaling pathways. The
specificity and efficacy of these engineered oHSV are currently evaluated in vitro in monolayers and 3D cultures and
will be soon characterized in vivo in an orthotopic xenograft model of GBM.
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